Eugia Pharma receives USFDA approval for Vancomycin Hydrochloride for Injection USP

The product is being launched in August 2023

Granules Pharmaceuticals successfully completes USFDA post marketing adverse drug experience inspection with zero observations

The inspection was conducted at Granules Pharmaceuticals Inc. (GPI) from July 31, 2023 to August 03, 2023

Biocon Biologics announces leadership appointments

Eugia Pharma receives USFDA approval for Plerixafor Injection

The approved product has an estimated market size of around US$ 210 million for the twelve months ending May 2023

Lupin receives approval from TGA Australia for Tiotropium Dry Powder

Tiotropium (as bromide monohydrate) 18 micrograms powder for inhalation in capsule

Biocon Biologics gets EMA’s positive opinion for an ophthalmology product

Lupin launches Luforbec 100/6 for adult asthma and COPD treatment in Germany

Luforbec® 100/6 pMDI aims to provide comprehensive support to patients and healthcare professionals

Lupin receives approval from USFDA for Chlorpromazine Hydrochloride Tablets USP

Chlorpromazine Hydrochloride Tablets USP had an estimated annual sale of USD 45 million in the U.S.

Granules India announces approval for Acetaminophen and Ibuprofen Tablets

This product will be launched through Granules Consumer Health (GCH) division

Aster DM Healthcare increases stake in Malabar Institute of Medical Sciences

Shareholding of the company in MIMS has increased from 76.01 per cent to 78.37 per cent